Ceribell CBLL 深 滬
已收盤 08-07 16:00:00 美东时间
18.81
+0.560
+3.07%
華盛通- 最 高18.875
- 今 開18.30
- 成交量 26.28万股
- 最 低 18.20
- 昨 收 18.25
- 總市值 71.37万
- 52周最高 24.33
- 市盈率 靜 --
- 換手率 692.60%
- 52周最低 10.85
- 委 比 -58.16%
- 總股本 3.79万
- 歷史最高 32.7489
- 量 比 0.81
- 振 幅 3.70%
- 歷史最低 10.01
- 每 手 1
- 風險率 3.63%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System
Ceribell, Inc. announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted a New Technology Add-on Payment (NTAP) of up to $2,171 per eligible Medicare patient case for its Delirium Monitor System. This follows the FDA clearance of the system in December 2025, making it the first FDA-cleared device for delirium screening and monitoring. The system continuously analyzes EEG segments to detect delirium patterns, supporting ra...
08-03 11:00
Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O’Keefe
Ceribell, a medical technology company, announced the appointments of Thomas West and Sharon O’Keefe to its Board of Directors. West, with extensive experience scaling medical technologies, previously led Nalu Medical and Intersect ENT, both acquired by large companies. O’Keefe, a seasoned health system leader, managed over $2 billion in revenue at the University of Chicago Medical Center. Their expertise will support Ceribell’s expansion of its ...
07-29 11:00
Ceribell to Report Second Quarter 2026 Financial Results on August 10, 2026
Ceribell, Inc. will release its second-quarter 2026 financial results on August 10, 2026, followed by a conference call at 1:30 p.m. PT / 4:30 p.m. ET. Investors can join via phone using the provided numbers and access code or through a live webcast on the company's website. Ceribell, based in Sunnyvale, California, specializes in neurological patient care with its FDA-cleared Ceribell System, an EEG platform for rapid diagnosis and monitoring. F...
07-20 20:05
CeriBell Highlights Publication Of New Research Paper, 'Point-Of-Care EEG Artificial Intelligence Measure Of Seizure Burden Associates With Clinical Outcome At Discharge'
CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that a new research paper
06-08 19:09
美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
Canaccord Genuity Maintains Buy on CeriBell, Lowers Price Target to $25
Canaccord Genuity analyst William Plovanic maintains CeriBell (NASDAQ:CBLL) with a Buy and lowers the price target from $28 to $25.
05-13 03:22
CeriBell shares are trading lower after the company reported mixed Q1 financial results.
CeriBell shares are trading lower after the company reported mixed Q1 financial...
05-13 00:21
CeriBell Q1 EPS $(0.52) Misses $(0.39) Estimate, Sales $26.494M Beat $26.088M Estimate
CeriBell (NASDAQ:CBLL) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.39) by 33.33 percent. This is a 44.44 percent decrease over losses of $(0.36) per share from the
05-12 04:09
Earnings Scheduled For May 11, 2026
Companies Reporting Before The Bell • United Parks & Resorts (NYSE:PRKS) is...
05-11 19:11
电话会总结 ｜ CeriBell(CBLL)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据CeriBell业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - Q4 2025营收2,480万美元，同比增长34% - 全年2025营收8,910万美元，同比增长36% - 产品收入：Q4为1,880万美元（同比增长33%），全年6,730万美元（同比增长34%） - 订阅收入：Q4为600万美元（同比增长37%），全年2,170万美元（同比增长41%） **盈利能力：** - 毛利率：Q4为87%，全年为88% - Q4毛利率较去年同期的88%略有下降，主要受中国进口产品关税上调的部分季度影响 - 全年毛利率
02-25 12:18
